Literature DB >> 25833692

Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Chuan Chen1, Dong-Ping Chen, Yan-Yan Gu, Liang-Hao Hu, Dan Wang, Jin-Huan Lin, Zhao-Shen Li, Jing Xu, Ge Wang.   

Abstract

Vascular invasion is one of the most important prognostic factors for patients with hepatocellular carcinoma (HCC). The objective of the current, retrospective study was to determine the associations of ascites and hepatitis B viral factors (HBeAg and anti-HBe status and HBV DNA levels), as well as tumor-related factors (size, tumor number, grade, and location) with micro- or macroscopic vascular invasion in patients with HCC that developed as a result of hepatitis B virus (HBV)-related cirrhosis. A total of 336 consecutive patients were included. Potential factors associated with micro- or macroscopic vascular invasion were analyzed by logistic regression. Ascites were more commonly detected in patients with micro- or macroscopic vascular invasion, and the presence of ascites was independently associated with vascular invasion. Among patients with mild-to-moderate or severe ascites, the odds ratio for macroscopic vascular invasion was 4.83 (95 % confidence interval [CI] 2.29-10.16) and 11.87 (95 % CI 4.53-31.07), respectively. Similarly, the presence of ascites was associated with microscopic vascular invasion (OR 5.00; 95 % CI 1.23-20.31). In contrast, hepatitis B viral factors were not significantly associated with vascular invasion. The presence of ascites was associated with vascular invasion in patients with HBV-related cirrhotic HCC. Thus, patients with ascites, vascular invasion should be considered and more frequent surveillance should be performed after curative treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25833692     DOI: 10.1007/s13277-015-3311-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  55 in total

1.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

2.  Recurrent hepatocellular carcinoma: it's the virus!

Authors:  W Ray Kim; Gregory J Gores
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Identification of melanoma biomarkers based on network modules by integrating the human signaling network with microarrays.

Authors:  Chunyun Huang; Youyu Sheng; Jack Jia; Lianjun Chen
Journal:  J Cancer Res Ther       Date:  2014-11       Impact factor: 1.805

4.  Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.

Authors:  J Figueras; L Ibañez; E Ramos; E Jaurrieta; J Ortiz-de-Urbina; F Pardo; J Mir; C Loinaz; L Herrera; P López-Cillero; J Santoyo
Journal:  Liver Transpl       Date:  2001-10       Impact factor: 5.799

5.  Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.

Authors:  Patrick P McHugh; Jeffrey Gilbert; Santiago Vera; Alvaro Koch; Dinesh Ranjan; Roberto Gedaly
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

6.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

Review 7.  Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.

Authors:  Charing Ching Ning Chong; Grace Lai Hung Wong; Paul Bo San Lai
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.

Authors:  Jing Xu; Jian Shi; Yi-Ping Wang; Yong Lin; Yue-Xiang Chen; Jian Lu; Xin Zeng; Wei-Fen Xie
Journal:  Med Sci Monit       Date:  2009-06

Review 9.  Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis.

Authors:  M Anzola
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

Review 10.  Risk of tumor cell seeding through biopsy and aspiration cytology.

Authors:  K Shyamala; H C Girish; Sanjay Murgod
Journal:  J Int Soc Prev Community Dent       Date:  2014-01
View more
  8 in total

1.  Possible associations between ascites and vascular invasion in patients with hepatocellular carcinoma.

Authors:  Ling Deng; Hong-Gui Qin; Chun Yang; Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2015-05-03

2.  Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.

Authors:  Masayuki Miyazaki; Masayoshi Yada; Kosuke Tanaka; Takeshi Senjyu; Takeshi Goya; Kenta Motomura; Motoyuki Kohjima; Masaki Kato; Akihide Masumoto; Kazuhiro Kotoh
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

3.  Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma.

Authors:  Xubiao Wei; Nan Li; Shanshan Li; Jie Shi; Weixing Guo; Yaxin Zheng; Shuqun Cheng
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

Review 4.  Need for normalization: the non-standard reference standard for microvascular invasion diagnosis in hepatocellular carcinoma.

Authors:  Hang-Tong Hu; Zhu Wang; Ming Kuang; Wei Wang
Journal:  World J Surg Oncol       Date:  2018-03-07       Impact factor: 2.754

5.  Effects of various interventions on the occurrence of macrovascular invasion of hepatocellular carcinoma after the baseline serum γ-glutamyltransferase stratification.

Authors:  Yao Liu; Qun Zhang; Xue Yang; Yuxin Li; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Xianbo Wang
Journal:  Onco Targets Ther       Date:  2019-02-28       Impact factor: 4.147

6.  A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma.

Authors:  Yao Liu; Le Sun; Fangyuan Gao; Xue Yang; Yuxin Li; Qun Zhang; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Ying Feng; Yuyong Jiang; Xianbo Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study.

Authors:  Chao-Wei Lee; Ming-Chin Yu; Gigin Lin; Jo-Chu Chiu; Meng-Han Chiang; Chang-Mu Sung; Yi-Chung Hsieh; Tony Kuo; Cheng-Yu Lin; Hsin-I Tsai
Journal:  World J Surg Oncol       Date:  2020-06-03       Impact factor: 2.754

8.  Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma.

Authors:  Michitaka Imai; Toru Ishikawa; Yuichi Kojima; Motoi Azumi; Yujiro Nozawa; Tomoe Sano; Akito Iwanaga; Terasu Honma; Toshiaki Yoshida
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.